Fig. 9.
Fig. 9. Sensitivity of the antibody epitopes on endomucin to treatment with glycosidases. bEND.3 cells either surface biotinylated (A) or unlabeled (B, C, and D) were subjected to immunoprecipitations with the antiendomucin MoAb V.5C7 (A and C), V.1A7 (B), or V.7C7 (D). Immunoprecipitated endomucin was either mock-treated (lane 1) or treated with endoglycosidase F (lane 2), O-glycosidase (lane 3), neuraminidase (lane 4), or neuraminidase and O-glycosidase (lane 5). After the enzyme treatment, endomucin was electrophoresed on a 10% polyacrylamide gel, transferred to nitrocellulose, and detected either with peroxidase-conjugated streptavidin followed by enhanced chemoluminescence (A) or by immunoblotting with the anti endomucin MoAb V.1A7 (B), V.5C7 (C), and V.7C7 (D). Molecular mass markers (in kilodaltons) are indicated on the left.

Sensitivity of the antibody epitopes on endomucin to treatment with glycosidases. bEND.3 cells either surface biotinylated (A) or unlabeled (B, C, and D) were subjected to immunoprecipitations with the antiendomucin MoAb V.5C7 (A and C), V.1A7 (B), or V.7C7 (D). Immunoprecipitated endomucin was either mock-treated (lane 1) or treated with endoglycosidase F (lane 2), O-glycosidase (lane 3), neuraminidase (lane 4), or neuraminidase and O-glycosidase (lane 5). After the enzyme treatment, endomucin was electrophoresed on a 10% polyacrylamide gel, transferred to nitrocellulose, and detected either with peroxidase-conjugated streptavidin followed by enhanced chemoluminescence (A) or by immunoblotting with the anti endomucin MoAb V.1A7 (B), V.5C7 (C), and V.7C7 (D). Molecular mass markers (in kilodaltons) are indicated on the left.

Close Modal

or Create an Account

Close Modal
Close Modal